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Schizophrenia is associated with brain glutamate dysfunction, but it is currently unclear 
whether antipsychotic administration can reduce the extent of glutamatergic abnormality. 
We conducted a systematic review of proton magnetic resonance spectroscopy 
(1H-MRS) studies examining the effects of antipsychotic treatment on brain glutamate 
levels in schizophrenia. The Medline database was searched to identify relevant articles 
published until December 2016. Inclusion required that studies examined longitudinal 
changes in brain glutamate metabolites in patients with schizophrenia before and after 
initiation of first antipsychotic treatment or a switch in antipsychotic treatment. The 
searches identified eight eligible articles, with baseline and follow-up measures in a total 
of 168 patients. The majority of articles reported a numerical reduction in brain glutamate 
metabolites with antipsychotic treatment, and the estimated overall mean reduction of 
6.5% in Glx (the combined signal from glutamate and glutamine) across brain regions. 
Significant reductions in glutamate metabolites in at least one brain region were reported 
in four of the eight studies, and none of the studies reported a significant glutamatergic 
increase after antipsychotic administration. Relationships between the degree of change 
in glutamate and the degree of improvement in symptoms have been inconsistent but 
may provide limited evidence that antipsychotic response may be associated with lower 
glutamate levels before treatment and a greater extent of glutamatergic reduction during 
treatment. Further longitudinal, prospective studies of glutamate and antipsychotic 
response are required to confirm these findings.
Keywords: schizophrenia, magnetic resonance spectroscopy, glutamates, antipsychotics, treatment response
iNTRODUCTiON
Animal, postmortem, and genetic studies indicate that schizophrenia is associated with abnormali-
ties in glutamatergic neurotransmission (1), but it is unclear whether antipsychotic treatment may 
impact on glutamate dysfunction in patients. Our recent meta-analysis suggests that schizophrenia 
is associated with a general elevation in glutamate metabolites, with some variation observed across 
brain regions and patient subgroups (2). Elevations in frontal cortical or hippocampal glutamate 
may lead to secondary elevations in striatal dopamine release, characteristic of schizophrenia (3–6). 
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Observations of glutamate dysfunction prior to illness onset 
(7–9), and in patients who are antipsychotic naïve or who have 
received minimal antipsychotic treatment (10, 11), suggest that 
glutamatergic dysregulation is a pathological feature of schizo-
phrenia, rather than an effect of antipsychotic exposure. However, 
it is unknown whether antipsychotic treatment can reduce, or 
indeed worsen, glutamatergic abnormalities. Potentially, modula-
tion of glutamatergic transmission with antipsychotic treatment 
could occur via downstream effects of D2 antagonism and/or via 
interactions at other receptor subtypes. Alternatively, if current 
antipsychotics do not adequately address glutamatergic dysfunc-
tion, this would support the suggestion that adjunctive treatment 
with glutamatergic agents may have additional therapeutic 
benefit.
The idea that antipsychotics may modulate glutamatergic 
neurotransmission is supported by experimental animal studies 
showing a reduction in frontal cortical glutamate following 
administration of some, but not all antipsychotics (12–19). In 
rodents, decreases in frontal glutamate have been observed using 
ex vivo proton nuclear magnetic resonance (1H-NMR) following 
administration of clozapine and olanzapine, but not haloperidol, 
risperidone, or aripiprazole (12). In vivo microdialysis studies 
in rodents have demonstrated reductions in pharmacologically 
induced elevations in frontal glutamate by risperidone, pali-
peridone, clozapine, aripipirazole, olanzapine, and haloperidol 
(13–19). However, a lack of significant effects of haloperidol on 
resting or stimulated glutamate metabolites in the rat brain have 
also been reported (19–22), and when antipsychotics are admin-
istered in the absence of pharmacologically stimulated glutamate 
release, antipsychotic-induced glutamate elevations may also 
be observed (23, 24). Together, these studies may suggest that 
antipsychotic glutamate-modulatory effects may be dependent 
on the animal model or glutamatergic assay, as well as the level 
of basal glutamatergic tone. Differential effects of antipsychotics 
may also be mediated by differing receptor binding profiles, and 
it has been suggested that downregulation of 5HT2A receptors 
by antipsychotics with high 5HT2A affinity may be important in 
reducing glutamatergic signaling (15, 16).
In man, brain glutamate levels can be measured in vivo using 
proton magnetic resonance spectroscopy (1H-MRS), usually 
within a specific a  priori brain region of interest. Depending 
on the achieved resolution, 1H-MRS can provide concentra-
tion estimates for glutamate and glutamine or, at lower field 
strengths, the combined glutamate plus glutamine signal, which 
is termed Glx. The idea that antipsychotics may reduce glutamate 
elevation in schizophrenia is supported by a cross-sectional study 
that detected an elevation in Glx in non-medicated, but not in 
medicated schizophrenia (25). In our recent meta-analysis, meta-
regression showed no significant relationship between regional 
glutamate, glutamine, or Glx and mean chlorpromazine equiva-
lent antipsychotic dose (2). Nonetheless, longitudinal studies 
examining glutamate metabolites before and after antipsychotic 
treatment are required to address this question directly. Several 
such studies have now been published and the purpose of this 
article is to provide systematic review of their findings.
As a second objective, we also review the relationships between 
glutamate and symptomatic response in longitudinal studies of 
antipsychotic treatment. Cross-sectional 1H-MRS studies show 
that glutamate metabolite levels differ between patients who 
have or have not responded well to antipsychotic treatment 
(26–29). This may suggest that glutamate level may predict the 
degree to which symptoms are likely to respond to antipsychotic 
administration, or that symptom reduction occurs in parallel 
with antipsychotic glutamatergic modulation. We, therefore, 
appraised the evidence from longitudinal studies for the value 
of glutamate levels in predicting or monitoring antipsychotic 
response.
MeTHODS
Study Selection
The review was conducted in accordance with PRISMA guide-
lines (30). The Medline electronic database was searched to iden-
tify journal articles published until 19 December 2016, using the 
following freeform and MeSH search terms: (“GLUTAMATE” 
OR “GLX”) AND (“SPECTROSCOPY” OR “MRS”) AND 
(“ANTIPSYCHOTIC”) AND (“SCHIZOPHRENIA” OR 
“PSYCHOSIS”). Reference lists of the returned articles were 
hand searched for further relevant publications.
Inclusion required that articles were published in peer-
reviewed journals in English or English translation. Inclusion also 
required that studies reported 1H-MRS glutamate, glutamine, or 
Glx before and after either first initiation of antipsychotic medi-
cation or initiation of a change in antipsychotic administration. 
Inclusion was limited to investigations performed in patients 
with first episode psychosis, schizophrenia, or schizoaffective 
disorder. Where separate articles reported overlapping datasets, 
the article reporting the largest dataset was included. Where arti-
cles reported glutamate measures over multiple time-points, the 
glutamate measure at longest time-point was included to provide 
maximal time for any antipsychotic effects to emerge.
Returned articles were initially screened for inclusion through 
reading of article titles and abstracts. Full text was then screened 
for articles potentially meeting the inclusion criteria. Two authors 
independently performed the searches and identified articles for 
inclusion (Akarmi Bhachu and Alice Egerton).
Data extraction
For qualitative comparison of antipsychotic-induced change in 
glutamate metabolites across studies, the percentage difference in 
glutamatergic metabolite level over the antipsychotic treatment 
period was extracted from each article. This was calculated as the 
percentage mean difference (PMD), where PMD = [(mean gluta-
mate metabolite level after treatment − mean glutamate metabo-
lite level before treatment)/mean glutamate metabolite level 
before treatment] × 100. Where these values were not reported 
(31, 32), they were extracted from figures using WebPlotDigitizer 
(http://arohatgi.info/WebPlotDigitizer). Extracted data also 
included the reported statistical significance of the change in glu-
tamatergic metabolite over the antipsychotic treatment period, 
the demographic and clinical characteristics of the sample, the 
antipsychotic/s prescribed and the duration of treatment, and the 
brain region investigated.
TABLe 1 | Methodological characteristics of studies investigating the effects of antipsychotics on brain glutamate measures.
Reference N Age illness stage DOi AP regime AP Pre-baseline AP Months
(32) 34 NR NR NR NR Hal; Tfpz; Pzd; Clz Naïve or >6 months w/o 1–6
(38) 14 NR SZ NR Fixed Ol Conventional AP, no w/o 2
(40) 14 32 ± 7 SZ 9 ± 6 Fixed Ri >7 days 2
(10) 7 27 ± 9 FEP 0.6 ± 0.8 Flexible Qu, Ri, Ar, Hal Lifetime exposure <3 weeks 12
(31) 17 25 ± 7 FEP 1.8 ± 2 Flexible Hal, Zpx, Ri, Ol, Qu, Zip; Clz Naïve 80
(34) 42 32 ± 6 SZ 0.2 ± 0.5 Flexible Ri, Ol, Clz, Pz, Cpz, Ppz w/o >7 days 1.4–2.1
(39) 16 31 ± 12 FEP NR Flexible Ri, Olz, Ar, Qu NR 6
(37) 24 27 ± 8 FEP 0.4 ± 0.5 Fixed Ri Naïve 1
Age, mean ± SD years; AP, antipsychotic; DOI, mean ± SD duration of illness in years; FEP, first episode psychosis; N, number of patients completing the follow-up assessment; 
NR, not reported; SZ, schizophrenia; w/o, washout period; Ar, aripiprazole; Clz, clozapine; Hal, haloperidol; Ol, olanzapine; Ppz, perperazine; Pz, perazinze; Pzd, pimozide; Qu, 
quetiapine; Ri, risperidone; Tfpz, trifluoperazine; Zip, ziprasidone; Zpx, zuclopenthixol.
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ReSULTS
The initial search identified 51 articles, of which 40 were excluded 
at the title and abstract screening stage. At the full-text screening, 
one study was excluded as it was not available in English (33). 
Analysis of the sample reported in Ref. (34) was subsequently 
extended (35). One article (36) was excluded as it reported a sub-
sample of participants included in a larger cohort and longer term 
follow-up (31). This resulted in final inclusion of eight original 
articles (10, 31, 32, 34, 37–40).
Methodological Characteristics
The methodological characteristics of the included articles are 
provided in Table 1. Eight articles provided glutamate measures 
at baseline and after antipsychotic administration in a total of 
168 patients. The sample sizes completing to 1H-MRS follow-up 
ranged from 7 to 42 patients. Three studies recruited patients 
with first episode psychosis who were antipsychotic naïve or had 
received minimal antipsychotic exposure (10, 31, 37). A further 
study in first episode psychosis did not describe antipsychotic 
exposure prior to baseline glutamatergic measurement (39). Two 
studies in chronic schizophrenia included washout periods of at 
least 7 days prior to baseline glutamate measurement and antipsy-
chotic re-initiation (34, 40). One study in chronic schizophrenia 
investigated the change in glutamate measures following a switch 
from conventional antipsychotic treatment to olanzapine and did 
not include a washout period (38). The final study did not specify 
stage of illness, but included only patients who were antipsychotic 
naïve or antipsychotic-free for a minimum of 6 months (32).
The majority of studies examined glutamatergic change in 
samples including patients on a variety of typical and atypical 
antipsychotic drugs, administered as standard clinical care (10, 31, 
32, 34, 39) (Table  1). The remaining three studies investigated 
specific antipsychotic compounds, with one study investigating 
olanzapine (38) and two studies investigating risperidone (37, 40). 
The antipsychotic treatment period ranged from 1 to 80 months.
Four studies acquired glutamate measures at a field strength of 
1.5-T and, therefore, reported glutamate primarily as the combined 
Glx signal (32, 34, 38, 40). Two studies were performed at 3-T, 
one of which reported Glx (39) and one of which reported both 
glutamate and Glx (37). The remaining two studies, performed 
at 4-T, reported glutamate, glutamine (10, 31), and Glx (31). 
Glutamatergic measures were reported as water-scaled values 
in ratio to voxel creatine (Cr) (32, 34, 38–40) or corrected for 
voxel cerebrospinal fluid (CSF) content (10, 31, 37). Brain regions 
investigated included the frontal cortex (seven studies), thalamus 
(four studies), temporal cortex (two studies), basal ganglia or 
striatum (two studies), parieto–occipital cortex (one study), and 
cerebellum (one study) (Table 2).
effect of Antipsychotic Treatment  
on Brain Glutamate Levels
Across brain regions, the PMD in Glx after antipsychotic treat-
ment ranged from a 12.5% increase (38) to a 27% decrease 
(39). In the majority of observations (10 out of 15), there was 
a numerical reduction in Glx, with an overall mean decrease of 
6.5% (Figure 1). The PMD in Glx could not be calculated from 
the information available in one article (10). A decrease in Glx 
of 6.5% (±11%) can be estimated to be associated with an effect 
size of approximately dz = 0.6. Accordingly, this translates to a 
within-subjects’ sample size of 24 patients to observe a significant 
change in Glx over antipsychotic treatment, at 80% power and 
α = 0.05, two-tailed.
Four of the eight included studies reported statistically 
significant glutamatergic reductions over antipsychotic treat-
ment in at least one brain region investigated (31, 34, 37, 39). 
Specifically, significant reductions in Glx occurred in the thala-
mus over 80 months of mixed antipsychotic administration (31), 
in the left temporal lobe over 2 months of mixed antipsychotic 
administration (34), and in the frontal lobe over 6 months of 
mixed antipsychotic administration (39), and in glutamate 
in right striatum over 1  month of risperidone administration 
(37). Additionally, Choe et al. (32) also reported a reduction in 
prefrontal cortical Glx over 1–6 months antipsychotic treatment 
in 29/34 patients but did not report the statistical outcome asso-
ciated with this finding. Extraction and analysis of data from 
the figure provided in the article found a significant reduction 
in frontal cortical Glx [mean ± SD Glx at baseline: 0.95 ± 0.30; 
follow-up: 0.75  ±  0.31; paired samples t-test: t(29)  =  3.06; 
P = 0.005]. There were no reports of significant increases in glu-
tamate metabolites with antipsychotic treatment. Three of the 
eight studies did not report significant effects of antipsychotic 
treatment on glutamate measures in any brain area across the 
patient sample (10, 38, 40).
FiGURe 1 | Percentage mean difference (PMD) in Glx in individual studies of Glx at baseline and after antipsychotic administration in schizophrenia. 
PMD was calculated as [(mean Glx level at after treatment−mean Glx level before treatment)/mean Glx level before treatment] × 100. Abbreviations: Glx, combined 
signal from glutamate and glutamine; Temp. ctx, temporal cortex; POC, parieto–occipital cortex; Cblm, cerebellum. Letters relate to articles as follows: A (32) B (38) 
C (40) D (34) E (31) F (39) G (40) H (34) I (31) J (40) K (34) L (39) M (37) N (39) O (37). *Reported as significant finding; aSignificance calculated from figure in article.
TABLe 2 | Results of studies investigating the effects of antipsychotics on brain glutamate measures and relationships with symptoms.
Reference voxel location Field  
strength (T)
Glutamate  
measure
PMD Relationships with symptom change
(32) FC 1.5 Glx/Cr  −21a,b Positive correlation between ΔGlx and ΔBPRS score
(38) R. ACC 1.5 Glx/Cr +12 NS correlation between ΔGlx and ΔSANS total score. Sig. increase in Glx 
in responders (+46%) compared to non-responders (−21%)L. ACC
(40) L. FC 1.5 Glx/Cr −7 NS correlation between ΔGlx and ΔPANSS
L. TC −16
L. Thal 0.5
(10) ACC 4 Glu; Gln; /CSF NA
L. FWM
L. Thal
(31) L. ACC 4 Glx; Glu; Gln; /CSF 5, 5, 4 Positive correlation between ΔGlx in L. Thal and Life Skills Profile Rating 
Scale score at follow-upL. Thal Glx; Glu; Gln; /CSF −9a,−1, −16
(34) L. FC 1.5 Glx/Cr −6 NS correlation between ΔGlx in temporal lobe and ΔPANSS
L. TC −15a
L. Thal 2
(39) FC 3 Glx/Cr −27a NS correlations between ΔGlx and ΔPANSS
L. BG −14
POC −5
(37) R. Striatum Cblm 3 Glx; Glu; /CSF −5; −7a Negative correlation between both ΔGlx and ΔGlu in R. striatum and 
ΔPANSS general scoreGlx; Glu; /CSF +9; +3
ACC, anterior cingulate cortex; BG, basal ganglia; BRPS, Brief Psychiatric Rating Scale; Cblm, cerebellum; Cr, scaled to voxel creatine; CSF, corrected for voxel cerebrospinal fluid 
content; Δ, change; L, left; FC, frontal cortex; FWM, frontal white matter; Gln, glutamine: Glu, glutamate; Glx, glutamate plus glutamine; NA, not available; NS, non-significant; 
PANSS, positive and negative syndrome scale for schizophrenia; PMD, percentage mean difference; POC, parieto–occipital cortex; R, right; SANS, scale for assessment of negative 
symptoms; TC, temporal cortex; Thal, thalamus.
aReported as significant finding.
bSignificance calculated from figure in article.
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Relationships between Change in 
Glutamate and Symptom Reduction  
on Antipsychotic Administration
The included studies reported mixed findings regarding associa-
tions between the degree of change in glutamate and the degree 
of symptomatic reduction with antipsychotic treatment (Table 2). 
Significant positive associations were reported for change in frontal 
Glx and change in the total score on the Brief Psychiatric Rating 
Scale (BPRS) (32), and for change in striatal glutamate and Glx and 
change in Positive and Negative Syndrome Scale (PANSS) general 
symptom score (37). One study reported a positive correlation 
between the change in thalamic Glx over 80 months antipsychotic 
treatment and Life Skills Profile Rating Scale Score at 80 months 
(31). These observations suggest that a greater degree of glutamate 
reduction is associated with a greater degree of symptomatic 
improvement during antipsychotic treatment. However, four of the 
eight included studies reported no significant correlations between 
changes in glutamate metabolite levels and changes in symptom 
severity (34, 38–40). While one of these studies found no signifi-
cant correlation between change in glutamate and change in the 
Scale for Assessment of Negative Symptoms (SANS) total score on 
olanzapine administration (38), a secondary analysis dividing the 
group into responders and non-responders based on the change 
in SANS total score found a 46% Glx increase in responders, com-
pared to a 21% Glx decrease in non-responders, and a significant 
difference between these groups (38). This is broadly inconsistent 
with the reports of positive associations between glutamate reduc-
tion and symptom reduction (32, 37).
None of the studies included in the review examined whether 
glutamate measures before antipsychotic treatment predicted 
the degree of subsequent symptomatic response to antipsychotic 
administration. However, a separate article (35) presenting addi-
tional analysis of data presented in a previous article (34) found 
that frontal Glx at baseline was significantly lower in subsequent 
responders than non-responders.
DiSCUSSiON
The main finding of this review is that the majority of studies 
reported a numerical reduction in glutamate metabolites follow-
ing antipsychotic treatment in schizophrenia, with half of the 
reviewed studies finding significant reductions in at least one 
brain region. In contrast, no significant increases in glutamate 
metabolites were reported. Schizophrenia is associated with 
a general increase in glutamate metabolites, which varies with 
region and with illness stage (2). This review provides some sug-
gestion that antipsychotics may reduce glutamatergic elevations 
in schizophrenia but indicates that this effect may be relatively 
small or limited to subgroups of patients.
The mean change in Glx over antipsychotic treatment was 
estimated from the available data as a decrease in the range of 
6.5% across regions, which would require a within-subjects’ 
sample size of 24 patients to achieve 80% power. Only three of 
the eight available studies had sample sizes of 24 or more patients 
(32, 34, 37) and the three studies with the smallest sample sizes 
(10, 38, 40) were the studies that did not find significant effects of 
antipsychotics on glutamatergic measures, suggesting that they 
may have been underpowered. Two of these smaller studies (38, 40) 
also differed in that they recruited patients with long antipsychotic 
medication histories, which may have also limited the ability to 
observe further glutamatergic reduction.
Our estimates of percentage reduction in glutamatergic 
metabolites following antipsychotic treatment in schizophrenia 
and the associated sample size calculations are limited by the 
availability of relatively few published studies. These studies 
have also investigated different brain regions, and glutamate 
dysfunction in schizophrenia may vary by region as well as by 
illness stage (2). In some cases, it was also necessary to extract 
values from published figures, which is less accurate than using 
reported values, and measures included both creatine-scaled or 
voxel CSF corrected data. As further studies become available, 
estimates of the percentage reduction can be updated and formal 
meta-analyses of effect sizes can be performed including inspec-
tion of potential influences such as regional specificity, patient 
subgroups, and duration of antipsychotic treatment. General 
limitations of 1H-MRS include the estimation of the total con-
centrations of glutamate metabolites in the voxel, rather than 
imaging of glutamate involved in neurotransmission specifically, 
and inability to resolve glutamate from glutamine at lower field 
strengths and thereby interpretation of the combined Glx signal. 
Advanced methodological approaches, such as 1H-MRS at high 
field strengths or 13C-MRS to inspect glutamate cycling may 
address some of these issues in future studies.
Reductions in glutamate metabolites following antipsychotic 
treatment would be consistent with the cross-sectional report of 
elevated prefrontal cortical Glx in non-antipsychotic medicated 
but not antipsychotic-medicated schizophrenia (25). While the 
mechanism by which antipsychotics might reduce glutamate is 
not yet clear, rodent studies also find reductions in basal or stimu-
lated glutamate following administration of some antipsychotics 
(12–19), which may relate to the 5HT2A antagonist activity of atypi-
cal agents (16, 41, 42). Atypical antipsychotics may also indirectly 
modulate glutamate release by modifying glutamatergic receptor 
activity or density (43–45). The majority of patients included 
in the reviewed studies were prescribed atypical antipsychotics, 
which may, therefore, have increased the potential to observe glu-
tamatergic reductions. Future studies could specifically compare 
the ability of D2-selective antipsychotics to antipsychotics with 
marked 5HT2A affinity to modulate glutamate in schizophrenia.
The timescales over which antipsychotic effects on glutamater-
gic measures have been evaluated range from 4  weeks (37) to 
7 years (31). It might be predicted that longer durations of antip-
sychotic treatment may be associated with progressive glutamate 
reductions. Across the included studies, there was not suggestion 
of this, for example significant decreases in frontal Glx were 
observed after administration of antipsychotics for 1–6 months 
(32, 39), but not 12 or 80  months (10, 31). Individual studies 
that included repeated glutamatergic measurement also do not 
evidence progressive glutamatergic reduction (10, 31). This may 
suggest that antipsychotic effects on glutamatergic systems are 
most apparent within the initial stages of treatment, which could 
be explored in future studies. A further consideration for longi-
tudinal assessment of glutamatergic measures in schizophrenia 
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is the potential interacting effects of other confounds, such 
as disease progression, aging effects, or volumetric changes. 
The study of longest duration detected correlations between 
the reductions in thalamic glutamine and gray matter loss in the 
superior temporal gyrus over 30 months (36), and gray matter 
loss in frontal, parietal, temporal, and limbic regions over 7 years 
(31), possibly reflecting excitotoxic processes.
The second aim of this article was to review the potential 
relationships between glutamate and the degree of antipsychotic 
response in longitudinal studies. Our review only identified 
one study prospectively examining the relationship between 
baseline glutamate and subsequent response, which reported 
higher baseline Glx/Cr across voxels in the frontal and temporal 
lobes and thalamus in subsequent antipsychotic non-responders 
than responders (35). Two studies also reported correlations 
between the extent of glutamatergic reduction and the extent 
of symptomatic improvement over the antipsychotic treatment 
period (32, 37). These findings are consistent with observations 
of higher frontal glutamate levels in some (26, 27, 46), but not 
all (29), cross-sectional studies comparing treatment-responsive 
and non-responsive schizophrenia, and of higher striatal Glx/Cr 
in treatment resistant compared to treatment-responsive patients 
(29). The observation that glutamate levels may predict antipsy-
chotic response (35) is also supported by recent pharmacogenomic 
findings that single nucleotide polymorphisms in genes encoding 
glutamatergic proteins associate with response to risperidone in 
first episode psychosis (47). In contrast, the conflicting result 
of an increase in frontal Glx/Cr in olanzapine responders com-
pared to non-responders was reported in one study (38), and 
several studies reported no correlations between glutamatergic 
change and symptomatic improvement (34, 38–40). The idea 
that antipsychotic administration is less effective in reducing 
glutamate and improving symptoms in patients with the highest 
levels of glutamate before treatment could be further explored 
through re-analysis of existing longitudinal 1H-MRS studies, and 
investigated in future longitudinal studies potentially combining 
glutamate 1H-MRS with glutamate genetic approaches.
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